Navigation Links
Blood Substitute Found Safe in Large Phase III Trial
Date:6/21/2008

It worked best in those under 80, could ease expected worldwide shortfall of supplies

FRIDAY, June 20 (HealthDay News) -- A blood substitute product called HBOC-201 proved safe and effective in a six-week Phase III multi-center clinical trial, a new study reports.

In all, 688 patients, ages 18 and older, who had elective orthopedic surgery initially received either one unit of blood (about one pint) or an equivalent one unit (65 grams) of HBOC-201, which is a hemoglobin-based oxygen carrier. Patients could receive up to 10 units of the blood substitute or unlimited blood transfusions over six days. The patients were evaluated daily and six weeks after their surgery.

Most of the 350 patients receiving the blood substitute used an average of five or less units, while the 338 patients receiving blood used less than two units on average.

"We found that we eliminated the need for blood transfusions for 59 percent of the 350 patients who received the blood substitute. The blood substitute worked best in those under 80 years old with a moderate transfusion need," study author Dr. Colin F. Mackenzie, professor and former director of the National Center for Trauma and EMS, University of Maryland School of Medicine, said in a prepared statement.

The blood substitute did not work as well as blood in patients over age 80 with more acute health issues and higher transfusion needs, and many of these patients were switched to regular blood.

Twenty-one of the older patients who received the blood substitute suffered a number of cardiac and central nervous system problems. Analysis revealed that these were due to advanced age, heart failure or possibly under-treatment, according to the researchers.

Death rates in patients with moderate transfusion needs who received either blood or the blood substitute were 1 percent. Death rates among patients with high transfusion needs were 5 percent in the blood substitute group and 3 percent in the blood group.

Common temporary side effects noted in patients who received the blood substitute included skin discoloration interpreted as jaundice, elevated blood pressure, and increased levels of the enzymes troponin and lipase.

The study, published in the June issue of the Journal of Trauma: Injury, Infection, and Critical Care, was funded by the Biopure Corporation, which makes HBOC-201.

The need to develop an alternative to red blood cells is being driven by a predicted shortfall of more than four million units of blood worldwide, according to background information in the study.

More information

America's Blood Centers has more about blood transfusions.



-- Robert Preidt



SOURCE: UCLA Health Sciences, news release, June 10, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Low Blood Sodium Predicts Mortality in PAH Patients
2. MetLife Foundation Partners with New York Blood Center to Introduce Donor Coach to New York Boroughs
3. Cord Blood America Says Pennsylvania Joins New York and California in Informing Parents of the Advantages of Umbilical Cord Blood Storage
4. New cancer treatment targets both tumor cells and blood vessels
5. Computers as safe as medical experts in prescribing blood thinning drugs
6. Tracking Top Number in Blood Pressure May Be Enough
7. High Blood Pressure in Kids Tracks Into Adulthood
8. ARKRAY USA Nationally Launches GLUCOCARD(TM) X-METER Blood Glucose Monitoring System
9. Spotting Vitamin-D Deficiency in the Absence of Symptoms: ZRT Laboratorys New, One-of-a-Kind Blood Spot Test Answers the Call for Early Detection of Rapidly Rising D-Deficiencies
10. AARP Michigan and American Red Cross Partner to Help Save Lives Through Blood Donation Drive
11. Cancer-killing viruses influence tumor blood-vessel growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: